期刊文献+

微RNA-34a在肝癌中的作用研究进展 被引量:4

Research progress of MicroRNA-34a in hepatocellular carcinoma
原文传递
导出
摘要 肝细胞癌(HCC)是世界范围内最常见的恶性肿瘤之一。微RNAs(miRNAs)是一类内源性非编码的单链RNAs,在恶性肿瘤的演变过程中发挥癌基因或抑癌基因作用。研究表明miRNAs在HCC的发生发展过程中发挥着重要作用。研究显示,miR-34a在多种肿瘤中表达下调,并参与肿瘤的发生及演变。目前,miR-34a在HCC发生发展中的作用已引起广泛关注。研究证实,miR-34a可通过调控靶基因的表达而影响HCC细胞的增殖、凋亡、侵袭和转移等多个关键生物学过程。本文就miR-34a在HCC中的作用研究进展做一综述。 Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide. MicroR- NAs (miRNAs) are a kind of endogenous non coding single- stranded RNAs, which can function as a tumor promoter or sup- pressor in the development and progression of human malignant tumors. Studies have shown that miRNAs play an important role in the occurrence and development of HCC. Numerous studies have found that the expression of miR-34a in various tumors is reduced and it participates in the carcinogenesis. Currently, the role of miR-34a in the tumorigenesis and development of HCC has attracted widespread attentions. Studies have confirmed that miR-34a can regulate the expression of its target genes and thus affect some key biological processes such as cell proliferation, apoptosis, invasion and metastasis of HCC. In this paper, we mainly reviewed the recent research progress on the role of miR-34a in HCC.
出处 《中华肝胆外科杂志》 CAS CSCD 北大核心 2016年第7期496-500,共5页 Chinese Journal of Hepatobiliary Surgery
基金 国家自然科学青年基金(81302059) 黑龙江省留学归国人员科研基金(LC2013C35) 黑龙江省教育厅面上基金(12541300)
关键词 微RNA 微R-34a 肝细胞癌 细胞增 MicroRNA, miR-34a Hepatocellularcarcinoma Cell proliferation Apoptosis Invasion Metastasis
  • 相关文献

参考文献33

  • 1Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015,65 (2) :87-108.
  • 2郑鹏飞,刘宏宇,叶研硕,李卓男,李巍.中晚期肝癌患者不同治疗方法的疗效比较:单中心回顾性研究[J].中华肝胆外科杂志,2014,20(11):781-785. 被引量:15
  • 3Yang N, Ekanem NR, Sakyi CA, et al. Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics [ J ]. Adv Drug Deliv Rev, 2015,81 : 62-74.
  • 4Chen F, Hu SJ. Effect of MicroRNA-34a in cell cycle, differentia- tion, and apoptosis: A review[ J]. J Biochem Mol Toxicol, 2012, 26(2) :79-86.
  • 5Pogribny IP, Tryndyak VP, Boyko A, et al. Induction of microR- NAome deregulation in rat liver by long-term tamoxifen exposure [ J3. Mutat Res, 2007,619 (1-2):30-37.
  • 6Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from ear- ly stages [ J ]. Toxicol Lett, 2011,200 ( 1-2 ) : 46-52.
  • 7Tryndyak VP, Kovalchuk O, Muskhelishvili L, et al. Epigenetic reprogramming of liver cells in tamoxifen-induced rat hepatocarci- nogenesis[ J]. Mol Carcinog, 2007,46 ( 3 ) : 187-197.
  • 8Li N, Fu H, Tie Y, et al. miR-34a inhibits migration and inva- sion by downregulation of c-Met expression in human hepatocellu- lar carcinoma cells[ J 1. Cancer Lett, 2009,275 ( 1 ) :44-53.
  • 9Pineau P, Volinia S, McJunkin K, et al. miR-221 overexpression contributes to liver tumorigenesis [ J ]. Proc Natl Acad Sci USA, 2010,107 ( 1 ) :264-269.
  • 10Lou W, Chen Q, Ma L, et al. Oncolytic adenovirus co-expressing miRNA-34a and IL-24 induces superior antitumor activity in ex- perimental tumor model[ J]. J Mol Med, 2013,91 (6) :715-725.

二级参考文献86

  • 1Ferlay J,Shin HR,Bray F,et al.Estimates of worldwide burden of cancer in 2008:GLOBOCAN 2008[J].Int J Cancer,2010,127(12):2893-2917.
  • 2Chen JG,Zhang SW.Liver cancer epidemic in China:past,present and future[J].Semin Cancer Biol,2011,21 (1):59-69.
  • 3Jemal A,Bray F,Center MM,et al.Global cancer statistics[J].CA:Cancer J Clin,2011,61 (2):69-90.
  • 4LIovet JM.Updated treatment approach to hepatocellular carcinoma[J].J Gastroenterol,2005,40(3):225-235.
  • 5Yang T,Lin C,Zhai J,et al.Surgical resection for advanced hepatocellular carcinoma according to Barcelona Clinic Liver Cancer (BCLC) staging[J].J Cancer Res Clin Oncol,2012,138(7):1121-1129.
  • 6Bruix J,Sherman M.Management of hepatocellular carcinoma:an update[J].H epatology,2011,53 (3):1020-1022.
  • 7Wang B,Xu H,Gao ZQ,et al.Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].Acta Radiol,2008,49(5):523-529.
  • 8Cheng AL,Kang YK,Chen Z,et al.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:a phase Ⅲ randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2009,10(1):25-34.
  • 9Liu L,Cao Y,Chen C,et al.Sorafenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis,and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):11851-11858.
  • 10Llovet JM,Ricci S,Mazzaferro V,et al.Sorafenib in advanced hepatocellular carcinoma[J].N Engl J Med,2008,359 (4):378-390.

共引文献50

同被引文献25

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部